NADAC acquisition cost data for SSD 1% CREAM. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 43598021040 | $0.0781 | 2022-12-21 | Rx |
| 43598021085 | $0.1244 | 2022-12-21 | Rx |
| 43598021050 | $0.1317 | 2022-12-21 | Rx |
| 43598021055 | $0.1317 | 2022-12-21 | Rx |
| 43598021025 | $0.1741 | 2022-12-21 | Rx |
| 43598021040 | $0.0781 | 2022-12-21 | Rx |
| 43598021085 | $0.1244 | 2022-12-21 | Rx |
| 43598021050 | $0.1317 | 2022-12-21 | Rx |
| 43598021055 | $0.1317 | 2022-12-21 | Rx |
| 43598021025 | $0.1741 | 2022-12-21 | Rx |
Generic: Silver Sulfadiazine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $6.5M | 303,870 | 201,398 | $0.1565 |
| 2020 | $5.9M | 282,234 | 185,047 | $0.1426 |
| 2021 | $5.7M | 300,478 | 197,224 | $0.1331 |
| 2022 | $5.6M | 283,219 | 189,243 | $0.1373 |
| 2023 | $4.6M | 222,662 | 153,462 | $0.1328 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $967.7K | 35,154 | 21,504 |
| California | $420.0K | 22,359 | 16,138 |
| New York | $405.3K | 19,284 | 11,884 |
| Texas | $289.4K | 16,077 | 12,095 |
| Pennsylvania | $180.7K | 9,706 | 6,281 |
| Michigan | $150.2K | 8,730 | 6,196 |
| North Carolina | $147.9K | 7,619 | 5,532 |
| Illinois | $142.8K | 7,408 | 5,388 |
| Puerto Rico | $134.8K | 4,647 | 3,106 |
| Arizona | $123.2K | 6,585 | 5,004 |
| Ohio | $115.0K | 6,493 | 4,509 |
| New Jersey | $105.1K | 5,707 | 3,901 |
| Kentucky | $94.7K | 4,473 | 2,921 |
| Georgia | $88.6K | 4,756 | 3,626 |
| Tennessee | $85.7K | 4,414 | 3,287 |
| Oklahoma | $84.1K | 4,012 | 2,835 |
| Alabama | $83.4K | 4,057 | 3,065 |
| Missouri | $71.2K | 4,113 | 3,045 |
| Wisconsin | $56.1K | 3,160 | 2,217 |
| Washington | $56.1K | 3,081 | 2,235 |
| Virginia | $52.4K | 3,099 | 2,276 |
| Maryland | $51.3K | 2,686 | 1,795 |
| Louisiana | $51.2K | 2,901 | 2,164 |
| Indiana | $48.8K | 2,803 | 1,997 |
| South Carolina | $48.3K | 2,749 | 2,018 |
| Massachusetts | $42.9K | 2,075 | 1,368 |
| Oregon | $42.2K | 1,984 | 1,439 |
| Arkansas | $37.9K | 2,159 | 1,621 |
| Nevada | $36.9K | 1,854 | 1,356 |
| Mississippi | $34.5K | 1,704 | 1,325 |
| Colorado | $31.2K | 1,546 | 1,116 |
| Iowa | $30.2K | 1,596 | 1,176 |
| West Virginia | $26.9K | 1,407 | 988 |
| Minnesota | $23.8K | 1,299 | 974 |
| Hawaii | $22.8K | 1,145 | 840 |
| Connecticut | $19.5K | 1,191 | 901 |
| Kansas | $19.4K | 1,142 | 862 |
| Nebraska | $15.4K | 855 | 630 |
| Utah | $13.8K | 831 | 635 |
| Maine | $13.6K | 534 | 371 |
| Delaware | $13.2K | 667 | 486 |
| New Mexico | $12.7K | 765 | 574 |
| Rhode Island | $12.7K | 636 | 400 |
| Idaho | $10.2K | 577 | 453 |
| Montana | $8.1K | 477 | 328 |
| New Hampshire | $7.9K | 440 | 313 |
| South Dakota | $7.7K | 436 | 334 |
| District of Columbia | $7.0K | 319 | 211 |
| North Dakota | $3.6K | 227 | 171 |
| Wyoming | $3.6K | 207 | 153 |
| Vermont | $3.5K | 215 | 145 |
| Alaska | $2.3K | 142 | 106 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.